Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Fabry disease is a rare genetic metabolic disorder caused by alpha-galactosidase A (alpha-gal A) deficiency.
• Current management lacks specific treatments, leading to severe complications like neuropathic pain, renal failure, and cardiovascular issues.

Purpose of the Study:

• To assess the safety and efficacy of intravenous alpha-gal A enzyme replacement therapy for Fabry disease.
• To evaluate the impact of alpha-gal A on neuropathic pain and key organ function.

Main Methods:

• A double-blind, placebo-controlled trial involving 26 adult male patients with confirmed Fabry disease.
• Patients received intravenous alpha-gal A (0.2 mg/kg) every other week for 12 doses.
• Neuropathic pain was assessed using the Brief Pain Inventory (BPI), alongside evaluations of renal function and cardiac conduction.

Main Results:

• Significant reduction in neuropathic pain scores (BPI) and improvement in pain-related quality of life in the alpha-gal A group compared to placebo.
• Histological analysis showed decreased mesangial widening in renal glomeruli for treated patients (P=.01).
• Improvements observed in creatinine clearance (P=.02), plasma glycosphingolipid levels, cardiac conduction, and body weight.

Conclusions:

• Intravenous alpha-gal A is a safe therapeutic option for Fabry disease.
• The enzyme replacement therapy demonstrates broad efficacy, alleviating pain and improving multiple organ system functions.
• This study supports enzyme replacement therapy as a viable treatment strategy for Fabry disease.